全文获取类型
收费全文 | 4001篇 |
免费 | 300篇 |
国内免费 | 77篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 38篇 |
妇产科学 | 92篇 |
基础医学 | 223篇 |
口腔科学 | 4篇 |
临床医学 | 176篇 |
内科学 | 400篇 |
皮肤病学 | 21篇 |
神经病学 | 17篇 |
特种医学 | 71篇 |
外国民族医学 | 2篇 |
外科学 | 430篇 |
综合类 | 367篇 |
预防医学 | 170篇 |
眼科学 | 5篇 |
药学 | 84篇 |
中国医学 | 13篇 |
肿瘤学 | 2244篇 |
出版年
2023年 | 23篇 |
2022年 | 46篇 |
2021年 | 37篇 |
2020年 | 35篇 |
2019年 | 23篇 |
2018年 | 59篇 |
2017年 | 53篇 |
2016年 | 63篇 |
2015年 | 67篇 |
2014年 | 65篇 |
2013年 | 72篇 |
2012年 | 194篇 |
2011年 | 217篇 |
2010年 | 111篇 |
2009年 | 99篇 |
2008年 | 227篇 |
2007年 | 249篇 |
2006年 | 243篇 |
2005年 | 256篇 |
2004年 | 329篇 |
2003年 | 369篇 |
2002年 | 284篇 |
2001年 | 267篇 |
2000年 | 150篇 |
1999年 | 126篇 |
1998年 | 79篇 |
1997年 | 73篇 |
1996年 | 47篇 |
1995年 | 31篇 |
1994年 | 72篇 |
1993年 | 78篇 |
1992年 | 72篇 |
1991年 | 66篇 |
1990年 | 58篇 |
1989年 | 34篇 |
1988年 | 15篇 |
1987年 | 20篇 |
1986年 | 18篇 |
1985年 | 12篇 |
1984年 | 8篇 |
1983年 | 7篇 |
1982年 | 4篇 |
1981年 | 5篇 |
1979年 | 2篇 |
1977年 | 2篇 |
1975年 | 2篇 |
1974年 | 2篇 |
1972年 | 1篇 |
1969年 | 1篇 |
1961年 | 1篇 |
排序方式: 共有4378条查询结果,搜索用时 31 毫秒
991.
Pignata S Scambia G Pisano C Breda E Di Maio M Greggi S Ferrandina G Lorusso D Zagonel V Febbraro A Riva N De Rosa V Gallo C Perrone F;Multicentre Italian Trials in Ovarian Cancer Gynecologic Malignancies Group 《British journal of cancer》2007,96(11):1639-1643
Anthracyclines and platinum derivates are active drugs for advanced endometrial carcinoma (AEC), but new schedules with higher efficacy and better tolerability are needed. A phase II study was conducted to describe activity and tolerability of carboplatin (C)+pegylated liposomal doxorubicin (PLD) in patients with AEC. Patients with chemonaive AEC, PS < or = 2, aged < 75 years, with at least one measurable lesion were eligible. Treatment was C (area under curve 5)+PLD (40 mg m(-2)) on day 1 every 4 weeks, up to six cycles. Forty-two patients were needed in a single-stage design, with at least 13 objective responses to define the treatment active. Forty-two patients were enrolled. Median age was 64 years (31-74). A total of 64% of patients were recurrent while 36% were advanced. Three complete (7%) and 22 partial responses (52%) were observed, for an overall response rate of 59.5% (95% exact CI: 43.3-74.3). One death potentially related to treatment was recorded (death at home for unknown reasons after 6th cycle). Other relevant toxicities (% of patients) were grade 3/4 neutropaenia 33%/14%, febrile neutropaenia 5%, grade 3/4 thrombocytopaenia 17%/5%, grade 3/4 anaemia 31%/2%. Skin toxicity was mild: grade 1 14%, grade 2 10%, grade 3 5%. Hair loss: complete 5%, partial 12%. The combination of carboplatin and PLD shows good activity and favourable toxicity as first-line chemotherapy of patients with AEC, deserving further studies in this setting. 相似文献
992.
Schippinger W Samonigg H Schaberl-Moser R Greil R Thödtmann R Tschmelitsch J Jagoditsch M Steger GG Jakesz R Herbst F Hofbauer F Rabl H Wohlmuth P Gnant M Thaler J;Austrian Breast Colorectal Cancer Study Group 《British journal of cancer》2007,97(8):1021-1027
The purpose of this trial was to investigate the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in stage II colon cancer. Patients with stage II colon cancer were randomised to either adjuvant chemotherapy with 5-FU/LV (100 mg m(-2) LV+450 mg m(-2) 5-FU weekly, weeks 1-6, in 8 weeks cycles x 7) or surveillance only. Five hundred patients were evaluable for analyses. After a median follow-up of 95.6 months, 55 of 252 patients (21.8%) have died in the 5-FU/LV arm and 58 of 248 patients (23.4%) in the surveillance arm. There was no statistically significant difference in overall survival (OS) between the two treatment arms (hazard ratios, HR 0.88, 95% CI 0.61-1.27, P=0.49). The relative risk for tumour relapse was higher for patients on the surveillance arm than for those on the 5-FU/LV arm; however, this difference was not statistically significant (HR 0.69, 95% CI 0.45-1.06, P=0.09). Consequently, disease-free survival (DFS) was not significantly different between the two trial arms. In conclusion, results of this trial demonstrate a trend to a lower risk for relapse in patients treated with adjuvant 5-FU/LV for stage II colon cancer. However, in this study with limited power to detect small differences between the study arms, adjuvant chemotherapy failed to significantly improve DFS and OS. 相似文献
993.
Gayther SA Song H Ramus SJ Kjaer SK Whittemore AS Quaye L Tyrer J Shadforth D Hogdall E Hogdall C Blaeker J DiCioccio R McGuire V Webb PM Beesley J Green AC Whiteman DC;Australian Ovarian Cancer Study Group Goodman MT Lurie G Carney ME Modugno F Ness RB Edwards RP Moysich KB Goode EL Couch FJ Cunningham JM Sellers TA Wu AH Pike MC Iversen ES Marks JR Garcia-Closas M Brinton L Lissowska J Peplonska B Easton DF Jacobs I Ponder BA Schildkraut J Pearce CL Chenevix-Trench G Berchuck A 《Cancer research》2007,67(7):3027-3035
High-risk susceptibility genes explain <40% of the excess risk of familial ovarian cancer. Therefore, other ovarian cancer susceptibility genes are likely to exist. We have used a single nucleotide polymorphism (SNP)-tagging approach to evaluate common variants in 13 genes involved in cell cycle control-CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, and CDKN2D-and risk of invasive epithelial ovarian cancer. We used a two-stage, multicenter, case-control study. In stage 1, 88 SNPs that tag common variation in these genes were genotyped in three studies from the United Kingdom, United States, and Denmark ( approximately 1,500 cases and 2,500 controls). Genotype frequencies in cases and controls were compared using logistic regression. In stage 2, eight other studies from Australia, Poland, and the United States ( approximately 2,000 cases and approximately 3,200 controls) were genotyped for the five most significant SNPs from stage 1. No SNP was significant in the stage 2 data alone. Using the combined stages 1 and 2 data set, CDKN2A rs3731257 and CDKN1B rs2066827 were associated with disease risk (unadjusted P trend = 0.008 and 0.036, respectively), but these were not significant after adjusting for multiple testing. Carrying the minor allele of these SNPs was found to be associated with reduced risk [OR, 0.91 (0.85-0.98) for rs3731257; and OR, 0.93 (0.87-0.995) for rs2066827]. In conclusion, we have found evidence that a single tagged SNP in both the CDKN2A and CDKN1B genes may be associated with reduced ovarian cancer risk. This study highlights the need for multicenter collaborations for genetic association studies. 相似文献
994.
International Agency for Research on Cancer Working Group on artificial ultraviolet 《International journal of cancer. Journal international du cancer》2007,120(5):1116-1122
Exposure to solar ultraviolet (UV) radiation is a known cause of skin cancer. Sunbed use represents an increasingly frequent source of artificial UV exposure in light-skinned populations. To assess the available evidence of the association between sunbed use and cutaneous malignant melanoma (melanoma) and other skin cancers, a systematic review of the literature till March 2006 on epidemiological and biological studies on sunbed use was performed in Pubmed, ISI Web of Science, Embase, Pascal, Cochrane library, Lilacs and Medcarib. Search for keywords in the title and in the abstract was done systematically and supplemented by manual searches. Only case-control, cohort or cross-sectional studies were selected. Data were abstracted by means of a standardized data-collection protocol. Based on 19 informative studies, ever-use of sunbeds was positively associated with melanoma (summary relative risk, 1.15; 95% CI, 1.00-1.31), although there was no consistent evidence of a dose-response relationship. First exposure to sunbeds before 35 years of age significantly increased the risk of melanoma, based on 7 informative studies (summary relative risk, 1.75; 95% CI, 1.35-2.26). The summary relative risk of 3 studies of squamous cell carcinoma showed an increased risk. For basal cell carcinoma, the studies did not support an association. The evidence does not support a protective effect of the use of sunbeds against damage to the skin from subsequent sun exposure. Young adults should be discouraged from using indoor tanning equipment and restricted access to sunbeds by minors should be strongly considered. 相似文献
995.
996.
Kerlikowske K Miglioretti DL Buist DS Walker R Carney PA;National Cancer Institute-Sponsored Breast Cancer Surveillance Consortium 《Journal of the National Cancer Institute》2007,99(17):1335-1339
Whether a recent large decline in use of postmenopausal hormone therapy after the release of the Women's Health Initiative findings in July 2002 and/or a decline in screening mammography use is related to a recently reported decline in breast cancer incidence in the United States is controversial. We prospectively collected data from four screening mammography registries from January 1997 through December 2003 for 603411 screening mammography examinations performed on women aged 50-69 years. Of these women, 3238 were diagnosed with breast cancer within 12 months of a screening examination. We calculated quarterly rates of self-reported current postmenopausal hormone therapy use and of invasive breast cancer, ductal carcinoma in situ (DCIS), and estrogen receptor (ER)-positive invasive breast cancer adjusted for age, registry, and time between screening examinations. All statistical tests were two-sided. Between 2000 and 2002 and between 2002 and 2003, annual rates of postmenopausal hormone therapy use declined by 7% and 34%, respectively (P(trend) < .001 for both). Between 2000 and 2003, annual rates of invasive cancer declined by 5% (P(trend) = .003). Between 2001 and 2003, annual rates of ER-positive invasive breast cancer declined by 13% (P(trend) = .002). Rates of DCIS were stable during the study period. Our finding of a statistically significant decline in the rate of ER-positive invasive breast cancer in a screening mammography population after the start of a concomitant substantial decline in postmenopausal hormone therapy use suggests that a decline in screening mammography rates is unlikely to account for the recent decline in US breast cancer incidence. 相似文献
997.
998.
999.
American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography 总被引:21,自引:0,他引:21
Saslow D Boetes C Burke W Harms S Leach MO Lehman CD Morris E Pisano E Schnall M Sener S Smith RA Warner E Yaffe M Andrews KS Russell CA;American Cancer Society Breast Cancer Advisory Group 《CA: a cancer journal for clinicians》2007,57(2):75-89
New evidence on breast Magnetic Resonance Imaging (MRI) screening has become available since the American Cancer Society (ACS) last issued guidelines for the early detection of breast cancer in 2003. A guideline panel has reviewed this evidence and developed new recommendations for women at different defined levels of risk. Screening MRI is recommended for women with an approximately 20-25% or greater lifetime risk of breast cancer, including women with a strong family history of breast or ovarian cancer and women who were treated for Hodgkin disease. There are several risk subgroups for which the available data are insufficient to recommend for or against screening, including women with a personal history of breast cancer, carcinoma in situ, atypical hyperplasia, and extremely dense breasts on mammography. Diagnostic uses of MRI were not considered to be within the scope of this review. 相似文献
1000.
Perry J Laperriere N Zuraw L Chambers A Spithoff K Cairncross JG;Neuro-oncology Disease Site Group;Cancer Care Ontario Program in Evidence-Based Care 《The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques》2007,34(4):402-410
OBJECTIVE: This systematic review examines the role of chemotherapy following surgery and external beam radiotherapy for adults with newly diagnosed malignant glioma. METHODS: MEDLINE, EMBASE, and the Cochrane Library databases were searched to August 2006 to identify relevant randomized controlled trials (RCTs) and meta-analyses. Proceedings from the 1997 to 2006 annual meetings of the American Society of Clinical Oncology were also searched. RESULTS: Two RCTs reported a survival advantage in favour of radiotherapy with concomitant and adjuvant temozolomide compared with radiotherapy alone in patients with anaplastic astrocytoma or glioblastoma. Twenty-six RCTs and two meta-analyses detected either no advantage or a small survival advantage in favour of adjuvant chemotherapy. CONCLUSION: Concomitant temozolomide during radiotherapy and post-radiation adjuvant temozolomide is recommended for all patients ages 18-70 with newly diagnosed glioblastoma multiforme who are fit for radical therapy (ECOG 0-1). Temozolomide may be considered in other situations (i.e., ECOG 2, biopsy only, age > 70, intermediate grade glioma), but there is no high-level evidence to support this decision. Moreover, there are few data on long-term toxicities or quality of life with temozolomide. Adjuvant chemotherapy may be an option for younger patients with anaplastic (grade 3) astrocytoma and patients with pure or mixed oligodendroglioma. However, there is no evidence of a survival advantage from adjuvant chemotherapy in these patients, and treatment-related adverse effects and their impact upon quality of life are poorly studied. The combination of procarbazine, lomustine, and vincristine (PCV) is not recommended for patients with anaplastic oligodendroglioma and oligoastrocytoma. 相似文献